XORTX Therapeutics Inc
XRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.3M
Close$
$0.61
56.9% downside
Current Fair Value
56.9% downsideOvervalued by 56.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.30 Million |
|---|---|
| Enterprise Value | $1.30 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.8 |
| Beta | 0.08 |
| Outstanding Shares | 1,617,707 |
Return
| Return on Equity | -71.12% |
|---|---|
| Return on Assets | -63.30% |
| Return on Invested Capital | -71.38% |
Valuation & Multiples
| P/E Ratio | -0.31 |
|---|---|
| PEG | -0.24 |
| Price to Sales | - |
| Price to Book Ratio | 0.47 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.50%▲ 2.50% |
|---|---|
| Total Invested | $92,839▲ 488526.32% |
| Investors Holding | 6▲ 5.00% |
ESG Score
No data
About XORTX Therapeutics Inc
CEO: Allen Davidoff